JavaScript must be enabled in order for you to fully use this site. However, it seems JavaScript is either disabled or not supported by your browser. To use this site, enable JavaScript by changing your browser options, then try again.
More
Black Hills Regional Eye Institute Toll Free: Click For Map & Directions
A Phase 3, Double-Masked, Multicenter, Randomized, Active Treatment-Controlled Study of the efficacy and safety of 0.5 mg and 2.0 mg Ranibizumab administered monthly or on an as-needed basis (PRN) in patients with Subfoveal Neovascular Age-Related Macular Degeneration.
Candidates for this study include the treatment of naïve patients with subfoveal choroidal neovascular membrane secondary to age-related macular degeneration.
www.gene.com/gene/research/